Stocks
Intelligent OutlookBIIB-
Intelligent Outlook
BIIB-
Prev Close-
50D MA-
200D MA-
52W High-
Live Price
BIIB 24H Rolling
0.000.00%0.00
Rolling: Last 24h | 5m
BIIB
Asset Information
Company Profile
Company:BIIB
Sector:Biotechnology
Industry:Biotechnology
Country:US
Employees:7,605
IPO Date:1991-09-17
Website:www.biogen.com/
Technicals & Growth
Market Cap:$22.51B
Shares O/S:146,702,272
52W High:$179.20
52W Low:$110.04
50D MA:$144.86
200D MA:$135.32
Financial Ratios
P/E Ratio:13.97
EPS:$10.98
Profit Margin:13.07%
ROE (TTM):7.08%
ROA (TTM):4.39%
BIIB
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Loading chart library...
Financial Data (Macrotrends)
Historical Data
Loading...